Netherlands· NL-0aca289fddb6
Nustendi 180 mg/10 mg filmomhulde tabletten
A bempedoic acid and ezetimibe product containing bempedoïnezuur + ezetimib, registered in Netherlands by DAIICHI SANKYO EUROPE GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Bempedoic acid and ezetimibe is registered in 10 of 19 countries.
Countries holding a registration under ATC C10BA10 (bempedoic acid and ezetimibe), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Bempedoic acid and ezetimibe · ATC C10BA10
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- BEMPEDOÏNEZUUR + EZETIMIB
- Manufacturer
- DAIICHI SANKYO EUROPE GmbH
- Country
- Netherlands (NL)
- ATC code
- C10BA10
- ATC class
- Bempedoic acid and ezetimibe
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/20/1424
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bempedoic acid and ezetimibe in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNUSTENDIDaiichi Sankyo Europe GmbH, Mnichov
- United KingdomNustendi 180mg/10mg tabletsPilsco Ltd
- United StatesNexlizetEsperion Therapeutics, Inc.
- SwitzerlandNustendi 180 mg / 10 mg, FilmtablettenDaiichi Sankyo (Schweiz) AG
- SpainNUSTENDI 180 mg/10 mg COMPRIMIDOS RECUBIERTOS CON PELICULADaiichi Sankyo Europe Gmbh
- IcelandNustendiDAIICHI SANKYO EUROPE GmbH*
- PolandNustendiDaiichi Sankyo Europe GmbH
- SwedenNustendi 180 mg/10 mg Filmdragerad tablettDaiichi Sankyo Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nustendi
- Liechtenstein · Nustendi
- Norway · Nustendi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2a263581-abf5-4b6d-931e-dd4878b51561 GET /v1/drugs/2a263581-abf5-4b6d-931e-dd4878b51561?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/nustendi-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Bempedoic Acid And Ezetimibe",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp124557",
"excipients": [
"BRILJANTBLAUW FCF ALUMINIUMLAK (E133)",
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"GLYCEROL MONOCAPRYLOCAPRAAT, TYPE I",
"HYPROLOSE (E 463)",
"INDIGOKARMIJN ALUMINIUMLAK (E 132)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMLAURILSULFAAT",
"NATRIUMZETMEELGLYCOLAAT",
"POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
"POVIDON K 30 (E 1201)",
"SILICIUMDIOXIDE (E 551)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"BEMPEDOÏNEZUUR",
"EZETIMIB"
],
"leaflet_url": null,
"authorised_at": "2020/03/27",
"procedure_number": "EMEA/H/C/004959",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/20/1424",
"additional_monitoring": "N"
}See everything about bempedoic acid and ezetimibe.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.